A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer |
| |
Authors: | Muellner Markus K Uras Iris Z Gapp Bianca V Kerzendorfer Claudia Smida Michal Lechtermann Hannelore Craig-Mueller Nils Colinge Jacques Duernberger Gerhard Nijman Sebastian M B |
| |
Institution: | CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. |
| |
Abstract: | Linking the molecular aberrations of cancer to drug responses could guide treatment choice and identify new therapeutic applications. However, there has been no systematic approach for analyzing gene-drug interactions in human cells. Here we establish a multiplexed assay to study the cellular fitness of a panel of engineered isogenic cancer cells in response to a collection of drugs, enabling the systematic analysis of thousands of gene-drug interactions. Applying this approach to breast cancer revealed various synthetic-lethal interactions and drug-resistance mechanisms, some of which were known, thereby validating the method. NOTCH pathway activation, which occurs frequently in breast cancer, unexpectedly conferred resistance to phosphoinositide 3-kinase (PI3K) inhibitors, which are currently undergoing clinical trials in breast cancer patients. NOTCH1 and downstream induction of c-MYC over-rode the dependency of cells on the PI3K-mTOR pathway for proliferation. These data reveal a new mechanism of resistance to PI3K inhibitors with direct clinical implications. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|